MDER (Medera) Short-Term Debt: $8.49 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Medera Short-Term Debt?

Medera MDER Short-Term Debt is $8.49 Mil as of Jun. 2024.

Medera's Short-Term Debt for the quarter that ended in Jun. 2024 was $8.49 Mil.

Medera's quarterly Short-Term Debt increased from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($9.30 Mil) but then declined from Dec. 2023 ($9.30 Mil) to Jun. 2024 ($8.49 Mil).

Medera's annual Short-Term Debt increased from . 20 ($0.00 Mil) to Dec. 2022 ($22.11 Mil) but then declined from Dec. 2022 ($22.11 Mil) to Dec. 2023 ($9.30 Mil).

Medera Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Medera Short-Term Debt Related Terms

Medera Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Medera's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medera Short-Term Debt Chart

Medera Annual Data
Trend Dec22 Dec23
Short-Term Debt
22.11 9.30

Medera Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
Short-Term Debt 22.11 0.00 9.30 8.49
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $8.49 Mil mean?
Medera (MDER) has a Short-Term Debt of $8.49 Mil as of Jun. 2024.
Is Medera's Short-Term Debt too high?
Medera's current Short-Term Debt is $8.49 Mil.
How does Medera's Short-Term Debt compare to ?
Medera's Short-Term Debt of $8.49 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Medera's current Short-Term Debt is $8.49 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medera stock overvalued right now?
Medera (MDER) has a current Short-Term Debt of $8.49 Mil. The current Short-Term Debt is $8.49 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Medera (MDER), the current Short-Term Debt is $8.49 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medera Business Description

Comparable Companies
Address 6 Tide Street, 2nd Floor, Boston, MA, USA, 02210
Medera Inc is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates through two arms, namely: (1) pre-clinical disease modeling and drug discovery under Medera's Novoheart brand, which includes its bioengineered human mini-heart technology platform and related state-of-the-art technologies for preclinical screening; and (2) clinical development of novel therapies under Medera's Sardocor brand, which aspires to create the shortest regulatory path to clinic for advancing next-generation gene therapies (by leveraging the above Novoheart platform), in particular, for cardiovascular diseases.